- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02392819
Effects on Metabolism and Cognitive Functions of a Commonly Used Commercial Food Supplement
September 2, 2015 updated by: Anne Nilsson, Lund University
Food Design for Improved Cognitive Performance
This project evaluate effects of a commonly used food supplement on glucose metabolism and cognitive function.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The test product has previously been suggested to elicit beneficial effects on glucose metabolism and cognitive performance.
The purpose with this study is to evaluate metabolic effects and effects on mood variables of the test product provided at breakfast.
Test variables are determined at fating and postprandial a standardised breakfast.
The results are compared with effects after a placebo product.
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Lund, Sweden, , SE-223 81 LUND
- Food for Health Science Centre, Medicon Village
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
38 years to 58 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age between 40-60 years, normal BMI, healthy, non-smokers
Exclusion Criteria:
- metabolic disorders or gastro- intestinal disease, intake of probiotics- or antibiotics during the last 2 weeks prior to the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: test product
Arm: Panax ginseng
|
Pananx ginseng is provided prior to a standardised breakfast, effects on test variables are determined at fasting and repeatedly postprandially the breakfast
|
Placebo Comparator: placebo product
Arm: a placebo with similar appearance but without Panax ginseng.
The tablet include all the other non-active bulk ingredients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
blood glucose
Time Frame: 4 hours
|
capillary blood glucose concentrations are determined at fasting and then repeatedly after a standardised breakfast
|
4 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
serum insulin
Time Frame: 4 hours
|
capillary serum insulin concentrations are determined at fasting and then repeatedly after a standardised breakfast
|
4 hours
|
Mood as measured by ratings on 100 mm visual analog scales( VAS rating scales)
Time Frame: 4 hours
|
measures of 6 mood variables (sad-glad, depressed-happy, displeased-pleased, dull-peppy, passive-Active, sleepy-awake) repeatedly in the postprandial period after breakfast
|
4 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Anne C Nilsson, PhD, Food for Health science Centre
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2015
Primary Completion (Actual)
June 1, 2015
Study Completion (Actual)
July 1, 2015
Study Registration Dates
First Submitted
March 2, 2015
First Submitted That Met QC Criteria
March 18, 2015
First Posted (Estimate)
March 19, 2015
Study Record Updates
Last Update Posted (Estimate)
September 3, 2015
Last Update Submitted That Met QC Criteria
September 2, 2015
Last Verified
September 1, 2015
More Information
Terms related to this study
Other Study ID Numbers
- LundU
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postprandial Blood Glucose Regulation
-
Lund UniversitySwedish Foundation for Strategic ResearchCompleted
-
Lund UniversitySwedish Foundation for Strategic ResearchCompleted
-
Lund UniversitySwedish Foundation for Strategic ResearchCompleted
-
San Diego State UniversityCompletedPostprandial Blood GlucoseUnited States
-
Glycemic Index Laboratories, IncCanadian Center for Functional Medicine; InovoBiologic Inc.CompletedBlood Glucose, PostprandialCanada
-
Marjukka KolehmainenCompletedHyperglycemia | Blood Glucose, Postprandial | Blood Insulin, PostprandialFinland
-
Oslo Metropolitan UniversityUniversity of Oslo; Nofima; Mills DACompletedGut Microbiota | Satiety | Postprandial Blood GlucoseNorway
-
Biofortis, Merieux NutriSciencesLonza Inc.Completed
-
Wageningen UniversityCompletedGlucose Metabolism | Postprandial Glucose ResponsesNetherlands
-
Northumbria UniversityPlant & food Research LtdCompletedPharmacodynamic Profile of 'Blackadder' Blackcurrant Juice Effects Upon the Monoamine Axis in HumansMonoamine Oxidase Inhibitor Activity | Prolactin Levels | Postprandial Blood Glucose
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States